Research
Hormonal
The depletion of Verrucomicrobia in obese-T2DM patients is associated with a loss of anti-inflammatory state and improved insulin sensitivity, potentially allowing the growth of pro-inflammatory Proteobacteria.
The study suggests that losing certain beneficial bacteria (like Verrucomicrobia) might contribute to insulin resistance. This highlights the importance of gut health in diabetes management, though it does not prescribe a specific probiotic or treatment.
ModerateSupportsMEDIUM confidence
Another important observation was the absence of Verrucomicrobia from obese-T2DM samples, and this phyla is considered as an efficient agent in maintaining the anti-inflammatory state of gut and improved insulin sensitivity... The depletion of Verrucomicrobia might have resulted in growth of rogue Protobacteria, such as Escherichia and Shigella.
Why this rating
Based on the same observational study; the causal link is suggested but not experimentally proven.
Source
Analysis of gut microbiota of obese individuals with type 2 diabetes and healthy individuals
Aftab Ahmad et al. · PLoS ONE · 2019
DOI 10.1371/journal.pone.0226372
cross_sectional · n=60Cited 192×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obese individuals with type 2 diabetes exhibit a distinct gut microbiota signature characterized by increased relative abundance of Firmicutes and decreased abundance of Verrucomicrobia, Bacteroidetes, and Proteobacteria compared to healthy controls.Moderate
- Increased abundance of gram-negative bacteria (Dialister and Allisonella) in obese-T2DM patients is associated with elevated lipopolysaccharide (LPS) levels, which mediates inflammatory response and contributes to insulin resistance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →